Lung cancer in never-smokers exhibits distinct biological characteristics, often leading to late-stage diagnoses due to lack of screening. Targeted therapies, guided by molecular testing, offer ...
The FDA approved the Oncomine Dx Express Test for rapid identification of NSCLC patients eligible for Zegfrovy treatment. The test provides results in 24 hours, aiding timely therapeutic decisions and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results